BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Adcetris brentuximab vedotin cancer data

Seattle Genetics said a second case of progressive multifocal leukoencephalopathy (PML) has been reported in a patient receiving Adcetris to treat lymphoma. The company, which noted that there is an "underlying rate of PML in lymphoma," said that the drug's label includes a warning that a fatal case of PML was reported in a...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >